Gaia/CLL13 – clinicaltrials.gov
CLL17 – https://www.dcllsg.de/en/trial/cll17/index.php
DCLLSG | CLL-RT1 Trial – Phase-II trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor, plus tislelizumab (BGB-A317), a PD1 inhibitor, for treatment of patients with Richter Transformation .
PreVent ACaLL – clinicaltrials.gov
Finished awaiting results:
Vision/HO141 – clinicaltrials.gov
CLL 14 – clinicaltrials.gov